Spero Therapeutics, Inc. — Director's Dealing 2021

Aug 30, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Spero Therapeutics, Inc. (SPRO)
CIK: 0001701108
Period of Report: 2021-08-26

Reporting Person: JOSEPH TAMARA L (Chief Legal Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-26	Common Stock	A	24067	$0.00	Acquired	24067	Direct

Footnotes

F1: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on August 26, 2022, subject to the Reporting Person's continued service through the applicable vesting date.